Wall Street unsure about Pfizer, but Starboard just bought $1B stake

Wall Street unsure about Pfizer, but Starboard just bought $1B stake
Will activist investor help solve drugmaker's post-pandemic challenges?
OCT 07, 2024
By 

Activist investor Starboard Value has taken a stake of about $1 billion in Pfizer Inc. and is seeking to spur a turnaround of the struggling pharmaceuticals giant, according to a person familiar with the matter.

Starboard has approached former Pfizer executives Ian Read and Frank D’Amelio to aid in its efforts, and they have expressed interest in helping, the person said, asking not to be identified discussing private information. It’s unclear in what capacity they would be involved. Read was Pfizer’s chief executive officer from 2010 to 2018 and chose current CEO Albert Bourla as his successor. D’Amelio was the New York-based company’s chief financial officer from 2007 to 2021. 

Starboard’s exact plans and engagement with the company aren’t clear at this time. The activist has found that investors and research analysts are frustrated by the company’s sustained post-pandemic struggles, the person said.

Pfizer declined to comment. Starboard couldn’t immediately be reached for comment outside normal business hours.

Shares in Pfizer rose 2.5% in premarket trading Monday, a move that would bring them into positive territory for the year. That compares with a 21% increase in 2024 for the S&P 500 index.

Pfizer has been struggling to find its next big hit. The company’s Covid-19 vaccine and treatment more than doubled its revenue, to $100 billion in 2022 from $42 billion in 2020, but demand for its Covid products has since declined dramatically.

UNCONVINCED

Wall Street has yet to be convinced Pfizer will be able to replace its pandemic riches. The company has seen its stock price more than halve from its high in December 2021. 

“It is not overly surprising to see a firm such as Starboard make an attempt to change the trajectory of the company,” Mizuho health-care specialist Jared Holz said in a note Sunday night. “The entire concept of PFE’s aggressive business development strategy and lack of return (so far) is likely one of the major reasons behind the Starboard stake.”

The stock might seem like the ideal target for an activist but “solving the many woes of Pfizer will likely take time,” BMO Capital Markets analyst Evan Seigerman said in a note.

The drugmaker has set its sights on cancer, acquiring a promising stable of cancer drugs in its $43 billion acquisition of Seagen Inc. last year. But the company has also experienced setbacks in trying to develop a pill for obesity, and earlier this year an experimental gene therapy for Duchenne muscular dystrophy failed in a large trial. Most recently, Pfizer announced the worldwide withdrawal of a drug for sickle cell anemia.

That drug came through Pfizer’s 2022 acquisition of Global Blood Therapeutics for $5.4 billion, one of a string of purchases that Starboard considers to have delivered poor results, the person said. Other recent buys include Biohaven for $11.6 billion and Arena Pharmaceuticals for $6.7 billion. 

In May, Pfizer embarked on a cost-cutting plan meant to save $1.5 billion by the end of 2027. Still, the person said, Starboard contrasts Pfizer’s current woes with the more positive trajectory it was on under its previous leadership team.

The Wall Street Journal reported earlier Sunday on Starboard’s Pfizer efforts.

Latest News

The fight over the CFPB is just beginning
The fight over the CFPB is just beginning

Locked out of their offices and told to stay home, employees at the Consumer Financial Protection Bureau have asked the courts to intervene as Elon Musk and Republican leaders move to shut down the agency that was established to protect people from predatory lending and financial scams.

Business-focused wealth tech RISR lands $8B Wealthcare Capital Management partnership
Business-focused wealth tech RISR lands $8B Wealthcare Capital Management partnership

Fintech platform interVal has also introduced a new feature to help advisors support entrepreneurial business owner clients better.

LPL boosts revenue potential with amped-up alts platform
LPL boosts revenue potential with amped-up alts platform

Along with greater revenue, alternative investments also carry risks, one industry lawyer noted.

How SageSpring Wealth Partners' next-gen strategy has fueled its success
How SageSpring Wealth Partners' next-gen strategy has fueled its success

President Jeff Dobyns unpacks the strategic power of mentorship, what makes an "ideal team player," and how the firm's 89 percent success rate has paid off for veteran advisors.

Powell heads for hot-seat hearings with ongoing pressure from Trump policies
Powell heads for hot-seat hearings with ongoing pressure from Trump policies

The Fed chair is in for some "hyper-charged" meetings, with legislators likely to raise questions on tariff threats and apparent steps to comply with anti-DEI orders.

SPONSORED Taylor Matthews on what's behind Farther's rapid growth

From 'no clients' to reshaping wealth management, Farther blends tech and trust to deliver family-office experience at scale.

SPONSORED Why wealth advisors should care about the future of federal tax policy

Blue Vault features expert strategies to harness for maximum client advantage.